Mike Rigby

Mike Rigby

Company: Bicycle Therapeutics

Job title: Project Leader

Seminars:

Live Discussion & Question Time 12:00 pm

Read more

day: Track B - Day 1 AM

BT8009: A Bicycle Toxin Conjugate Targeting Nectin-4 for the Treatment of Solid Tumours 11:40 am

BT8009 binds to Nectin-4 with high affinity and selectivity BTC format allows rapid tumour penetration and delivery of cytotoxic payload MMAE A Phase I/II trial of BT8009 is underway in patients with advanced solid tumours associated with Nectin-4 expressionRead more

day: Track B - Day 1 AM

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.